Cereber Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-07-2024
- Paid Up Capital ₹ 0.10 M
as on 09-07-2024
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 926.03%
(FY 2020)
- Profit 1823.39%
(FY 2020)
- Ebitda 5912.90%
(FY 2020)
- Net Worth 551.30%
(FY 2020)
- Total Assets 102.39%
(FY 2020)
About Cereber Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Firdose Syed and Shaikh Hamed serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PTC313428
- Company No.
313428
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Cereber Pharmaceuticals Private Limited offer?
Cereber Pharmaceuticals Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Immunosuppressive Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Sexual Wellness Products, Contraceptives, Anaemia Medicine, Common Disease Medicines, Brain & Nervous System Drugs, Immunomodulator Drugs.
Who are the key members and board of directors at Cereber Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Firdose Syed  | Director | 04-Sep-2018 | Current |
| Shaikh Hamed | Director | 04-Sep-2018 | Current |
Financial Performance and Corporate Structure Insights of Cereber Pharmaceuticals.
Cereber Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 926.03% increase. The company also saw a substantial improvement in profitability, with a 1823.39% increase in profit. The company's net worth Soared by an impressive increase of 551.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cereber Pharmaceuticals?
In 2019, Cereber Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cereber Pharmaceuticals?
Unlock and access historical data on people associated with Cereber Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cereber Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cereber Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
